

## **OPEN ACCESS**

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

\*CORRESPONDENCE
Frontiers Editorial Office
 research.integrity@frontiersin.org

RECEIVED 07 February 2024 ACCEPTED 10 February 2024 PUBLISHED 21 February 2024

## CITATION

Frontiers Editorial Office (2024) Retraction: The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer.

Front. Oncol. 14:1383383.
doi: 10.3389/fonc.2024.1383383

## COPYRIGHT

© 2024 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Retraction: The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer

Frontiers Editorial Office\*

## A Retraction of the Original Research Article:

The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer

by He X, Wang Z, Zhou Y and Feng Y (2023) Front. Oncol. 13:1132186. doi: 10.3389/fonc.2023.1132186

The journal retracts the 2023 article cited above.

Following publication, the publisher identified concerns regarding the scope and peer review of this article. A subsequent investigation, which was conducted in accordance with Frontiers' policies, found indicators of third-party involvement and inadequate peer review process. As the scientific integrity of the article cannot be guaranteed, and adhering to the recommendations of the Committee on Publication Ethics (COPE), the article is retracted.

The authors have not responded to this retraction.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers.